National Cancer Institute, Bethesda, MD.
National Cancer Institute, Bethesda, MD.
Urol Oncol. 2023 May;41(5):257.e1-257.e6. doi: 10.1016/j.urolonc.2023.03.007. Epub 2023 Apr 8.
The RENAL nephrometry score (RNS) is widely used to describe renal mass complexity and inform patient counseling for partial nephrectomy (PN). However, in cases with multiple tumors, it is unknown which features drive perioperative outcomes.
To employ a novel scoring equation (multiplex score [MS]) derived from RNS to assess outcomes of multiplex PN at our institution.
DESIGN, SETTING, AND PARTICIPANTS: A total of 62 consecutive multiplex PN (median (range) # tumors = 4(2-11), 65% robotic) were performed by a single surgeon. The MS was defined a priori as a weighted score derived from RNS (# low risk ([LR] lesions) + 2*(# intermediate risk [IR]) + 4*(# high risk [HR]) based on published complication rates.
MS was dichotomized into favorable/unfavorable based on median score. Patient outcomes were maintained prospectively. MS was compared with other potential RNS derived scoring systems.
A total of 249 tumors were scored. Median (range) MS was 6(range 2-20, IQR 3-8). Complications occurred in 10 patients (16.1%). Only 1 complication occurred in the favorable MS(<6) group, and MS was associated with perioperative complication (P = 0.02) and blood loss (P < .001). When compared to other potential scoring systems, MS had the best area under the curve (AUC) to predict operative complications (0.75).
The novel MS was associated with complications and blood loss. This tool may facilitate standardized reporting of complexity for multiplex series, with special relevance for hereditary cancer syndromes.
For patients who have one kidney tumor, there are established scoring systems to help patients and surgeons decide on the surgical plan. However currently, for patients with more than one renal tumor, there is no such scoring system. Here, we present the "Multiplex Score" to aid shared-decision-making in cases with more than one renal tumor.
肾肿瘤影像学评分(RNS)广泛用于描述肾脏肿块的复杂性,并为部分肾切除术(PN)患者提供咨询信息。然而,对于多发性肿瘤患者,尚不清楚哪些特征会影响围手术期的结果。
运用一种新的评分方程(多重评分[MS]),对本机构的多发性 PN 进行评估。
设计、设置和参与者:总共进行了 62 例连续的多发性 PN(中位数(范围)#肿瘤=4(2-11),65%为机器人),由一位外科医生完成。MS 是根据发表的并发症发生率,通过 RNS 预先定义的加权评分(#低危(LR)病变+2*#中危(IR)病变+4*#高危(HR)病变)。
根据 MS 的中位数,将其分为有利/不利两类。患者的预后结果是前瞻性的。比较了 MS 与其他潜在的 RNS 衍生评分系统。
共对 249 个肿瘤进行了评分。MS 的中位数(范围)为 6(范围 2-20,IQR 3-8)。10 例患者发生并发症(16.1%)。仅在 MS(<6)组中发生了 1 例并发症,MS 与围手术期并发症(P=0.02)和出血量(P<0.001)相关。与其他潜在评分系统相比,MS 对手术并发症的预测具有最佳的曲线下面积(AUC)(0.75)。
新的 MS 与并发症和出血量相关。该工具可能有助于对多发性肿瘤系列进行标准化的复杂性报告,对遗传性癌症综合征尤其重要。
对于单个肾脏肿瘤患者,已经有了确定的评分系统来帮助患者和外科医生决定手术方案。然而,对于多个肾脏肿瘤患者,目前还没有这样的评分系统。在这里,我们提出了“多重评分”,以帮助决策有多发性肾肿瘤的患者。